Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
M KreskenGerman Tigecycline Evaluation Surveillance Trial Study Group

Abstract

Tigecycline is a novel antimicrobial agent for parenteral use encompassing a broad spectrum of bacterial pathogens, including multi-resistant organisms. Here, we report the results of the first nationwide surveillance trial that was conducted in order to evaluate the susceptibility of bacterial isolates to tigecycline in a European country prior to its clinical use. A total of 2,610 Gram-positive and Gram-negative organisms recovered from hospitalized patients were tested. Minimum inhibitory concentrations (MICs) were determined using the microdilution method. All enterococci, staphylococci (including methicillin-resistant Staphylococcus aureus; MRSA), and streptococci tested were tigecycline-susceptible, except one isolate of Staphylococcus haemolyticus. Among the Gram-negative bacteria, 100% of the Escherichia coli isolates (including extended spectrum beta-lactamase [ESBL]-producers) were tigecycline-susceptible, while about 10% of the Enterobacter cloacae and Klebsiella pneumoniae isolates were resistant. Based on the results of this surveillance study, tigecycline may represent a suitable option most notably for the empiric treatment of bacterial mixed infections, including in clinical situations in which multi-resistant o...Continue Reading

References

Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Ad C FluitDana Milatovic
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patricia A BradfordPeter J Petersen
Aug 18, 2005·Diagnostic Microbiology and Infectious Disease·Daryl J HobanUNKNOWN Tigecycline Evaluation and Surveillance Trial (TEST Program) Group
Aug 27, 2005·The Journal of Antimicrobial Chemotherapy·David M Livermore
Jul 5, 2006·Seminars in Pediatric Surgery·Joseph F BuellE Steve Woodle
Oct 27, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee
Jan 19, 2007·The Journal of Antimicrobial Chemotherapy·Neil WoodfordDavid M Livermore
Aug 31, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F DrobniewskiUNKNOWN Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobi
Feb 21, 2008·The Journal of Antimicrobial Chemotherapy·Guido WernerIngo Klare

❮ Previous
Next ❯

Citations

Mar 20, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M KreskenC von Eiff
Feb 25, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M KreskenUNKNOWN Study Group
Apr 5, 2013·Clinical Microbiology Reviews·Alejandro BeceiroGermán Bou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.